(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment - 2Well known Worldwide Caf\u00e9s to Experience
- 3'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- 4Emergency services search for five people last seen in missing Jeep
- 5IDF: Staying in West Bank refugee camps will quell lone-wolf terror
- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
- Why screening for the deadliest cancer in the U.S. misses most cases
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- Kids with smartphones by age 12 are at higher risk of health issues, study finds
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- Man triggers smoke bomb during failed crypto robbery
- Israel's fractured opposition hands Netanyahu a full term
- Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- CDC vaccine panel delays vote to stop recommending hepatitis B shot at birth
